Neumora Therapeutics, Inc.
NMRA · Nasdaq · United States
Share price · NMRA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NMRA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026+35.0%
- 16 Oct 2026+11.0%
Nothing announced by NMRA that day or the session before.
- 15 Oct 2026+20.5%
Nothing announced by NMRA that day or the session before.
- 13 Oct 2026-15.3%
Nothing announced by NMRA that day or the session before.
- 30 Sep 2026-12.0%
Nothing announced by NMRA that day or the session before.
- 22 Sep 2026+12.5%
Nothing announced by NMRA that day or the session before.
- 15 Sep 2026-16.8%
Nothing announced by NMRA that day or the session before.
- 16 Jun 2026+70.6%
- 15 Jun 2026-48.6%
- 14 May 2026+10.7%
Nothing announced by NMRA that day or the session before.
Share of unusual movement by asset
For each asset, the share of NMRA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 54% |
| Sessions with no dated event | — | 46% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Vasopressin V1a receptorSmall molecule | Alzheimer's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $29M | $117M | $43M-$40M operating cash flow | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $39M | $147M | $53M-$46M operating cash flow | report ↗ |
| 2025-Q3 | — | $41M | $129M+ $42M short-term inv. | $57M-$47M operating cash flow | report ↗ |
| 2025-Q2 | — | $39M | $125M+ $93M short-term inv. | $53M-$52M operating cash flow | report ↗ |
| 2025-Q1 | — | $52M | $127M+ $122M short-term inv. | $68M-$59M operating cash flow | report ↗ |
| 2024-Q3 | — | $61M | $276M+ $66M short-term inv. | $73M-$33M operating cash flow | report ↗ |
| 2024-Q2 | — | $49M | $151M+ $221M short-term inv. | $59M-$56M operating cash flow | report ↗ |
| 2024-Q1 | — | $46M | $183M+ $240M short-term inv. | $54M-$43M operating cash flow | report ↗ |
| 2023-Q3 | — | $42M | $412M+ $97M short-term inv. | $53M-$48M operating cash flow | report ↗ |
| 2023-Q2 | — | $33M | $204M | $39M-$31M operating cash flow | report ↗ |
| 2023-Q1 | — | $29M | $211M | $36M-$33M operating cash flow | report ↗ |
| 2022-Q3 | — | $23M | $253M | $29M | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $176M | $183M | $59M-$206M operating cash flow | report ↗ |
Neumora reported no revenue for FY2025, with no prior-year figure disclosed. R&D expense was $176.1M, down 12.4% YoY from $200.9M, while cash and cash equivalents totaled $182.5M at year-end. The company posted a full-year net loss of $236.9M, compared with $243.8M in 2024.
Management guided that the year-end cash position should fund operations into Q3 2027. Clinical highlights included new pre-specified Phase 1b data for NMRA-511 in Alzheimer’s disease agitation, full enrollment of the navacaprant KOASTAL-2 and -3 studies with a joint topline readout expected in Q2 2026, selection of NMRA-898 as the lead M4 franchise program in schizophrenia, and NMRA-215 preclinical data supporting a planned clinical start in Q1 2027.
View 3 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $201M | $142M+ $165M short-term inv. | $61M-$183M operating cash flow | report ↗ |
| 2023-FY | — | $143M | $374M+ $80M short-term inv. | $59M-$163M operating cash flow | report ↗ |
| 2022-FY | — | $92M | $241M+ $131M short-term inv. | $33M-$115M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 15 sales ($784K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-21 | Aurora Daljit Singh · See Remarks | Option exercise | 20,553 | $0.72 | $15K | Form 4 |
| 2026-08-21 | Aurora Daljit Singh · See Remarks | Open-market sale | 20,553 | $1.59 | $33K | Form 4 |
| 2026-08-21 | Aurora Daljit Singh · See Remarks | Option exercise | 21,055 | $0.72 | $15K | Form 4 |
| 2026-08-21 | Aurora Daljit Singh · See Remarks | Open-market sale | 21,055 | $1.60 | $34K | Form 4 |
| 2026-08-21 | Aurora Daljit Singh · See Remarks | Option exercise (derivative) | 20,553 | — | — | Form 4 |
| 2026-08-21 | Aurora Daljit Singh · See Remarks | Option exercise (derivative) | 21,055 | — | — | Form 4 |
| 2026-08-20 | Pinto Joshua · director, President & CEO | Award / grant (derivative) | 500,000 | — | — | Form 4 |
| 2026-08-20 | Milligan Michael Lee · See Remarks | Award / grant (derivative) | 175,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 114 reporting institutions held 70.4M shares ($135.6M, 37.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Siren, L.L.C. | 8,497,822 | $16.6M |
| 2 | SOFTBANK GROUP CORP. | 6,090,301 | $11.9M |
| 3 | PERCEPTIVE ADVISORS LLC | 5,104,097 | $10.0M |
| 4 | MIC Capital Management UK LLP | 4,460,700 | $8.7M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3,891,893 | $7.6M |
| 6 | FMR LLC | 3,498,658 | $6.8M |
| 7 | WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 3,309,123 | $6.5M |
| 8 | MILLENNIUM MANAGEMENT LLC | 2,754,854 | $5.4M |
| 9 | ICONIQ Capital, LLC | 2,559,090 | $5.0M |
| 10 | Lunate Capital Ltd | 2,124,143 | $4.1M |
| 11 | BlackRock, Inc. | 2,054,316 | $4.0M |
| 12 | TWO SIGMA INVESTMENTS, LP | 2,036,692 | $4.0M |
| 13 | JOHNSON & JOHNSON | 1,849,445 | $3.6M |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 1,388,998 | $2.7M |
| 15 | Ikarian Capital, LLC | 1,278,408 | $2.5M |